Becton, Dickinson and Price Target Increased to $116.00 by Analysts at RBC Capital (BDX)
Equities research analysts at RBC Capital lifted their price objective on shares of Becton, Dickinson and (NYSE:BDX) from $113.00 to $116.00 in a research note issued to investors on Friday. RBC Capital’s price target points to a potential downside of 0.07% from the company’s current price.
Becton, Dickinson and (NYSE:BDX) traded down 0.14% during mid-day trading on Friday, hitting $116.08. The stock had a trading volume of 762,285 shares. Becton, Dickinson and has a 52-week low of $96.73 and a 52-week high of $120.66. The stock has a 50-day moving average of $118.6 and a 200-day moving average of $115.4. The company has a market cap of $22.427 billion and a price-to-earnings ratio of 24.25.
Becton, Dickinson and (NYSE:BDX) last announced its earnings results on Thursday, July 31st. The company reported $1.65 EPS for the quarter, missing the Thomson Reuters consensus estimate of $1.67 by $0.02. The company had revenue of $2.16 billion for the quarter, compared to the consensus estimate of $2.14 billion. During the same quarter in the prior year, the company posted $1.58 earnings per share. The company’s quarterly revenue was up 5.1% on a year-over-year basis. On average, analysts predict that Becton, Dickinson and will post $6.25 earnings per share for the current fiscal year.
The company also recently declared a quarterly dividend, which is scheduled for Tuesday, September 30th. Shareholders of record on Tuesday, September 9th will be given a dividend of $0.545 per share. This represents a $2.18 dividend on an annualized basis and a yield of 1.88%. The ex-dividend date of this dividend is Friday, September 5th.
Other equities research analysts have also recently issued reports about the stock. Analysts at Leerink Swann raised their price target on shares of Becton, Dickinson and from $117.00 to $120.00 in a research note on Friday. Separately, analysts at Deutsche Bank raised their price target on shares of Becton, Dickinson and from $119.00 to $123.00 in a research note on Friday. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Becton, Dickinson and in a research note on Friday. They now have a $122.00 price target on the stock. Two research analysts have rated the stock with a sell rating, five have given a hold rating and six have assigned a buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $113.23.
Becton Dickinson and Co is a global medical technology company engaged in the development, manufacture and sale of medical devices, instrument systems and reagents used by healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.